CellDetect urine test for detecting bladder cancer meets principal endpoint in multi-center clinical study Plans to Secure CE Mark for a European Release of the Non-Invasive Test and Submit a Pre-IDE to the U doxycycline-hcl.com/doxycycline-vs-stds-prostatitis-and-endometritis.html .S. FDA in 2015 BioLight Lifestyle Sciences Investments Ltd.4 percent and specificity of 82.7 percent for the research's primary endpoint. Due to these successful study outcomes, Micromedic plans to protected CE mark authorization for a European release of the non-invasive test later this year, as well concerning submit a Pre-IDE to the U.S.

drastic impact

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting Cell Therapeutics, Inc.D., at the Fox Chase Malignancy Center throughout a poster program at the AACR-NCI-EORTC International Meeting on Molecular Targets and Cancers Therapeutics kept October 19-23, 2013 in Boston, MA. Beeharry. The analysis assessed the mechanism of tumor cell killing induced by PIXUVRI in a number of cancer cell lines. The entire poster presentation is offered by www online.celltherapeutics.com/publications.